ADXS — Ayala Pharmaceuticals Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMicro CapMomentum Trap

Annual cashflow statement for Ayala Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2019 October 31st	2020 October 31st	2021 October 31st	2022 October 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-16.6	-26.5	-17.9	-14.4	-48.1
Depreciation
Amortisation
Non-Cash Items	3.41	5.14	1.34	-1.52	17.1
Unusual Items
Other Non-Cash Items
Changes in Working Capital	-24.4	-1.85	0.42	0.313	1.1
Change in Accounts Receivable
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Payable / Accrued Expenses
Change in Other Liabilities
Net Change in Other Assets & Liabilities
Cash from Operating Activities	-36.1	-21.9	-15.4	-15.3	-29.5
Capital Expenditures	-1.28	-0.748	-0.46	-0.201	—
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	0.083	—	0.449	0.035	5.95
Sale of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-1.2	-0.748	-0.011	-0.166	5.95
Financing Cash Flow Items	-0.001	0	0	-0.018	20
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	24.6	15.5	31.9	-0.956	26
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	-12.8	-7.18	16.4	-16.4	2.49